MYC and cancer: In support of this hypothesis, a novel potent ATP‐competitive inhibitor of CLK2 (T‐025; N2‐methyl‐N4‐[pyrimidin‐2‐ylmethyl]‐5‐[quinolin‐6‐yl]‐7H‐pyrrolo[2,3‐d]pyrimidine‐2,4‐diamine) exhibited particular efficacy in MYC amplified cancer cell lines [94].